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Description of the technology
Flow cytometry traditionally uses fluorochrome-labeled
probes, such as antibodies, to identify cells expressing the
targets of those probes. A sample stream carries single
cells in suspension past a laser, exciting the fluorochromes,
with quantitation of the emitted fluorescent signals from
each cell via optical filters and photomultiplier tubes [1].
In mass cytometry, or CyTOF, the fluorescent labels are
replaced with heavy metal ions. The metal ions are che-
lated to a polymer, which is covalently linked to antibodies
or other probes. After staining with these probes, single
cells are introduced via an aerosol stream into a plasma
torch, resulting in complete ionization of the labeled cells.
The heavy ions are then focused via a quadrapole and
enter a time-of-flight detector, where the individual ions
are quantitated [2, 3]. This results in the simultaneous
benefit of more available labels, with much less spillover
between detector channels (Fig. 1).
Type of data obtained/readout
Flow and mass cytometry uniquely allow for the quantita-
tion of multiple parameters on many individual cells. Up
to 17 or more parameters are possible with fluorescence,
while 40 or more parameters can be quantitated with mass
cytometry [4]. It is not unusual to collect data on 105–107
cells per sample by either technique. The data from each
sample is compiled in a Flow Cytometry Standard (FCS)
file, for both flow and mass cytometry. The FCS file lists
the intensities obtained for each probe on each individual
cell. Analysis of FCS files can be carried out in any of a
number of commercial software packages, and involves
sequential “gating” or selection of populations of interest.
For example, single cells might first be selected based on
light scatter parameters; then live cells gated by exclusion
of a viability dye; then lymphocytes identified by a com-
bination of forward and side-angle light scatter; then T
cells selected by expression of CD3; etc. Note that mass
cytometry does not allow for light scatter properties to be
measured, so all gating is done on the basis of labeled
probes, in addition to cell length (as measured by the time
duration of the cell’s ion cloud). Accurate quantitation of
the proportions of even rare populations of cells can be
made if enough events are collected; as can relative levels
of expression of cellular proteins such as activation
markers, intracellular cytokines, or signaling proteins. Ab-
solute cell counts and quantitation of molecules of bound
fluorophore/metal are also possible, for example, with ref-
erence to standardized labeled beads. Automated gating
algorithms are also available, including unsupervised clus-
tering and dimension reduction techniques [5–8].
Limitations of the approach
Pre-conjugated antibodies are now readily available for
both flow and mass cytometry, though the latter generally
still requires a few conjugates to be made in-house, in
order to complete a specific high-parameter panel. Sensi-
tivity to detect low-abundance proteins can be an issue for
both platforms. In general, the best fluorochromes have a
detection limit of about 40 molecules per cell, while the
detection limit for mass cytometry is about 400–500 mol-
ecules per cell. Sensitivity is influenced by factors such as
autofluorescence (in traditional flow cytometry) and non-
specifically bound antibodies (in both platforms). Com-
pensation for spectral overlap can reduce sensitivity and
introduce artifacts in fluorescence flow cytometry. In both
platforms, there can be loss of cells in sample preparation
washing steps, although mass cytometry generally requires
more washing steps than fluorescence assays. Additionally,
there are cell losses in the mass cytometer itself, such that
data are captured on only about 30 % of introduced cells
(improved to 50 % in the latest version of CyTOF
instrumentation). Collection speed is also much lower in
mass cytometry (300–500 events per second, compared to
several thousand events/second in fluorescence flow
cytometry).
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Types of samples needed and special issues
pertaining to samples
Cells for these assays need to be in single-cell suspen-
sion. Debris and cell aggregates can interfere with the
running of samples and with the interpretation of data.
Because of the potential for cell loss, samples with <105
cells are usually not appropriate for either flow or mass
cytometry. Functional assays, such as cytokine produc-
tion, or analysis of phospho-signaling proteins, require
cells with good viability. Overnight shipping of blood
and cryopreservation of PBMC can compromise these
readouts. Variability in sample handling, acquisition, and
analysis are all significant in affecting results [9]. Mul-
tiple approaches can mitigate these factors, from use of
lyophilized reagents [10] to “barcoding” of samples to
produce a single composite sample for purposes of uni-
form processing and acquisition [11–13].
Level of evidence
Flow cytometry is backed by thousands of publications
and over 30 years of development. Mass cytometry is
more recent, but has seen an exponential rise in publica-
tions. Several flow cytometry assays are used in FDA-
approved diagnostic tests. Both platforms can produce
strong evidence, provided that appropriate controls are
included.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HTM drafted the manuscript and AH added to and edited it. Both authors
read and approved the final manuscript.
Author details
1Institute for Immunity, Transplantation, and Infection, Stanford University
School of Medicine, Stanford, CA, USA. 2Centre Hospitalier Universitaire
Vaudois (CHUV), Epalinges, Switzerland.
Received: 31 July 2015 Accepted: 6 August 2015
References
1. Dunne JF, Maecker HT. Flow cytometry. In: Nijkamp FP, editor. Principles of
immunopharmacology F. Basel: Verlag; 2004. p. 183–96.
2. Ornatsky O, Bandura D, Baranov V, Nitz M, Winnik MA, Tanner S. Highly
multiparametric analysis by mass cytometry. J Immunol Methods.
2010;361:1–20.
3. Tanner SD, Baranov VI, Ornatsky OI, Bandura DR, George TC. An introduction
to mass cytometry: fundamentals and applications. Cancer Immunol
Immunother. 2013;62:955–65.
4. Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK. A deep profiler’s
guide to cytometry. Trends Immunol. 2012;33:323–32.
5. Aghaeepour N, Finak G, FlowCAP Consortium, DREAM Consortium, Hoos H,
Mosmann TR, et al. Critical assessment of automated flow cytometry data
analysis techniques. Nat Methods. 2013;10:228–38.
6. Bendall SC, Simonds EF, Qiu P, Amir EAD, Krutzik PO, Finck R, et al.
Single-cell mass cytometry of differential immune and drug responses
across a human hematopoietic continuum. Science. 2011;332:687–96.
7. Qiu P, Simonds EF, Bendall SC, Gibbs KD, Bruggner RV, Linderman MD, et al.
Extracting a cellular hierarchy from high-dimensional cytometry data with
SPADE. Nat Biotechnol. 2011;29:886–91.
8. Chester C, Maecker HT. Algorithmic Tools for Mining High-Dimensional
Cytometry Data. The Journal of Immunology 2015;195:773–9.
9. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping
for the Human Immunology Project. Nat Rev Immunol. 2012;12:191–200.
10. Maecker HT, Rinfret A, D’Souza P, Darden J, Roig E, Landry C, et al.
Standardization of cytokine flow cytometry assays. BMC Immunol. 2005;6:13.
11. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows
high-throughput drug screening and signaling profiling. Nat Methods.
2006;3:361–8.
12. Zunder ER, Finck R, Behbehani GK, Amir E-AD, Krishnaswamy S, Gonzalez
VD, et al. Palladium-based mass tag cell barcoding with a doublet-filtering
scheme and single-cell deconvolution algorithm. Nat Protoc. 2015;10:316–33.
13. Mei HE, Leipold MD, Schulz AR, Chester C, Maecker HT. Barcoding of live
human peripheral blood mononuclear cells for multiplexed mass cytometry.
J Immunol. 2015;194(4):2022–31.
Fig. 1 a Example of emission spectra of several dyes used in fluorescence flow cytometry, showing the degree of overlap and consequent
spillover between detectors. b Ion signals detected by mass cytometry are by comparison very discrete, allowing many more simultaneous
probes to be used, with little or no spillover
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